Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy units: a follow-up study.

I S Machín1, Robaina JCG, C Bonnet

  • 1Hospital Nuestra Señora de la Candelaria, Tenerife, Canary Islands, Spain. isanchez@comtf.es

Journal of Investigational Allergology & Clinical Immunology
|February 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambulatory introduction of foslevodopa/foscarbidopa in Parkinson's disease in private practice. Case series of the first 22 patients.

Revue neurologique·2026
Same author

Short Communication: True Cost Accounting (TCA) as a transformative approach for livestock agri-food systems.

Animal : an international journal of animal bioscience·2025
Same author

Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia.

Revue neurologique·2024
Same author

Megalencephaly secondary to a novel germline missense variant p.Asp322Tyr in AKT3 associated with growth hormone deficiency and central hypothyroidism: A case report.

American journal of medical genetics. Part A·2024
Same author

ENPP1 homozygous stop-loss variant causing generalized arterial calcifications of infancy: About a severe neonatal clinical case.

European journal of medical genetics·2023
Same author

Extracellular miR-6723-5p could serve as a biomarker of limbal epithelial stem/progenitor cell population.

Biomarker research·2022
Same journal

Safety, Adherence, and Effectiveness of an Increased Dose of Pollinex Quattro Grass and/or Olive in Real-World Practice.

Journal of investigational allergology & clinical immunology·2026
Same journal

Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial.

Journal of investigational allergology & clinical immunology·2026
Same journal

Severe Rituximab-Induced Cytokine Release Syndrome After Desensitization Successfully Treated With Tocilizumab: A Case Report.

Journal of investigational allergology & clinical immunology·2026
Same journal

Dysregulation of Mast Cell Prostaglandin in Food Anaphylaxis.

Journal of investigational allergology & clinical immunology·2026
Same journal

Extract-Negative Cofactor-Dependent Shrimp Anaphylaxis Caused by IgE Reactivity to Insoluble Muscle Proteins.

Journal of investigational allergology & clinical immunology·2026
Same journal

Antibiotic Allergy Labels in Hospitalized Patients: Results of a Multicenter Cross-Sectional Study.

Journal of investigational allergology & clinical immunology·2026
See all related articles

Allergy immunotherapy is safe, with a low rate of mild adverse reactions (0.8%). Most reactions were local or mild systemic events, rapidly reversible, highlighting the safety of immunotherapy units for allergic respiratory diseases.

Area of Science:

  • Clinical Immunology
  • Allergy Research
  • Immunotherapy Safety

Background:

  • Immunotherapy units are crucial in allergy and clinical immunology departments.
  • Assessing adverse reaction rates is vital for patient safety and treatment efficacy.

Purpose of the Study:

  • To determine the incidence and characteristics of adverse reactions during allergen immunotherapy.
  • To evaluate the safety profile of immunotherapy administered in a dedicated unit.

Main Methods:

  • Retrospective analysis of 5,108 immunotherapy doses administered to 339 patients over two years.
  • Categorization of adverse reactions by type, timing, allergen, and patient demographics.

Main Results:

  • A total of 0.8% of doses resulted in adverse reactions, with 0.4% being systemic and mild.

Related Experiment Videos

  • Most reactions (85.7%) occurred within 30 minutes post-injection, primarily large local reactions.
  • Systemic reactions were exclusively observed in asthmatic patients and were rapidly reversible.

    • Conclusions:

    • Allergen immunotherapy is a safe treatment for allergic respiratory diseases.
    • Immunotherapy units offer a controlled environment ensuring safe administration and management of adverse events.